NEW YORK (GenomeWeb News) – Bio-Rad Laboratories reported after the close of the market on Tuesday that its first-quarter revenues ramped up 3 percent year over year, as the company fell short of consensus analyst estimates on the top and bottom lines.

The Hercules, Calif.-based firm said that revenues for the three months ended March 31 totaled $499.7 million, up from $486.3 million a year ago, but below the average Wall Street estimate of $506.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.